Clinical Trial Update: A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating eltrombopag or placebo in combination with azacitidine for intermediate-1 to high-risk myelodysplastic syndromes was terminated with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thrombocytopaenia | Phase 3 | Status: TERMINATED | Results posted: 2017-12-12